Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

August 11, 2017: By Jon Swedien

Ocular Therapeutix logoOcular Therapeutix has named Daniel Bollag, PhD, its senior vice president, regulatory affairs, pharmacovigilance, and quality, the Bedford, Massachusetts, drugmaker announced Aug. 3.

Bollag served in similar roles at Ariad Pharmaceuticals and Genzyme.

He succeeds Eric Ankerud, who will remain with the company as a senior advisor and consultant.

“Dan’s expertise will be critical as we work towards resubmitting our new drug application (NDA) for Dextenza while continuing to advance our additional development programs,” Ocular Therapeutix CEO Antony Mattessich said.

In mid-July, Ocular Therapeutix received a complete response letter (CRL) from the US FDA for its resubmitted NDA for Dextenza, a proposed treatment for pain after ophthalmic surgery, over deficiencies in manufacturing and testing. It was Dextenza’s second CRL related to plant issues.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

FDA Warns that Vancomycin Eye Injections May Lead to Blindness

Alcon to Launch Clareon IOL at ESCRS Meeting

Bribery Trial Testimony Focuses on Melgen’s Billing for Lucentis

VSY Biotechnology to Launch AcrivaUD Trinova Trifocal IOL at ESCRS Meeting

Valeant Launches $1 Billion Private Senior Notes Offering

STAAR Surgical Appoints Scott Barnes, MD, as New CMO

Aerie Acquires Envisia Technology for $25M to Advance Retinal Program

Carl Zeiss Meditec Announces Milestone of 1 Million SMILE Procedures

Maryland Team Wins First Phase of NEI Contest to Create Human Retina

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022